The article reviews the evidence for the effectiveness of sodium-glucose cotransporter-2 (SGLT2) inhibitors in treating kidney diseases, particularly chronic kidney disease (CKD) and acute kidney injury (AKI). SGLT2 inhibitors are primarily used to treat type 2 diabetes by increasing glucose excretion in the urine, thereby lowering blood glucose levels. However, they have also shown cardioprotective effects and are used in heart failure treatment. In terms of their renal effects, SGLT2 inhibitors reduce intraglomerular pressure and albuminuria, which helps slow the decline in glomerular filtration rate (GFR) and has anti-inflammatory and antifibrotic properties. The review highlights several clinical studies demonstrating the nephroprotective effects of SGLT2 inhibitors, including reduced albuminuria, slower progression of CKD, and improved kidney function. Meta-analyses indicate the efficacy of SGLT2 inhibitors in kidney disease, especially in diabetes-related kidney disease. The article also discusses the pleiotropic effects of SGLT2 inhibitors, such as their impact on lipid levels, cardiovascular health, and cognitive function. Finally, it addresses the limitations and future perspectives of SGLT2 inhibitors in kidney disease, emphasizing the need for further research and careful patient selection.The article reviews the evidence for the effectiveness of sodium-glucose cotransporter-2 (SGLT2) inhibitors in treating kidney diseases, particularly chronic kidney disease (CKD) and acute kidney injury (AKI). SGLT2 inhibitors are primarily used to treat type 2 diabetes by increasing glucose excretion in the urine, thereby lowering blood glucose levels. However, they have also shown cardioprotective effects and are used in heart failure treatment. In terms of their renal effects, SGLT2 inhibitors reduce intraglomerular pressure and albuminuria, which helps slow the decline in glomerular filtration rate (GFR) and has anti-inflammatory and antifibrotic properties. The review highlights several clinical studies demonstrating the nephroprotective effects of SGLT2 inhibitors, including reduced albuminuria, slower progression of CKD, and improved kidney function. Meta-analyses indicate the efficacy of SGLT2 inhibitors in kidney disease, especially in diabetes-related kidney disease. The article also discusses the pleiotropic effects of SGLT2 inhibitors, such as their impact on lipid levels, cardiovascular health, and cognitive function. Finally, it addresses the limitations and future perspectives of SGLT2 inhibitors in kidney disease, emphasizing the need for further research and careful patient selection.